| First Author | Wang J | Year | 2018 |
| Journal | Front Immunol | Volume | 9 |
| Pages | 3157 | PubMed ID | 30693001 |
| Mgi Jnum | J:284223 | Mgi Id | MGI:6378124 |
| Doi | 10.3389/fimmu.2018.03157 | Citation | Wang J, et al. (2018) PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8(+) T Cell Responses. Front Immunol 9:3157 |
| abstractText | Cerebral malaria (CM), mainly caused by Plasmodium falciparum (P. f.), is one of the most lethal complications of severe malaria. As immunopathology mediated by brain-infiltrating CD8(+) T cells is the major pathogenesis of CM, there is no safe and efficient treatment clinically focused on CD8(+) T cells. New methods are needed to protect the host from injury. As evidence has shown that programmed death-1 (PD-1) is one of the most efficient immunomodulatory molecules, we constructed two soluble fusion proteins, PDL1-IgG1Fc and PDL2-IgG1Fc, to enhance PD-1/PDL signaling pathways in innate and adaptive immune cells, including macrophages and CD8(+) T cells. Firstly, we confirmed that PD-1 signal pathway deficiency led to higher levels of CD8(+) T cell proliferation and shorter survival time in PD-1-deficient (Pdcd1 (-/-)) mice than WT mice. Secondly, PDL1-IgG1Fc-treated mice exhibited a more prolonged survival time than control groups. Moreover, PDL1-IgG1Fc was observed to ameliorate blood-brain barrier (BBB) disruption by limiting the over-reactive CD8(+) T cell cytotoxicity during experimental cerebral malaria (ECM). Further studies found thatPDL1-IgG1Fc-treated macrophages showed significant suppression in macrophage M1 polarization and their antigen presentation capability to CD8(+) T cells. In conclusion, our results demonstrated that the administration of PDL1-IgG1Fc in the early stage before ECM onset has an obvious effect on the maintenance of immune microenvironment homeostasis in the brain and is deemed a promising candidate for protection against CM in the future. |
